Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 301–400 of 1,008
Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks
Kang, S. K., Kim, D., Shin, S. A., Kim, Y. K., Choi, H., & Lee, J. S. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264414 · Cited by 43
“Monoclonal antibodies such as aducanumab and donanemab are emerging as AD treatment drugs that target aggregated amyloid b to reduce its buildup in the brain ( 20,21 ).”
BackgroundKrishnadas, N., Doré, V., Robertson, J. S., Ward, L., Fowler, C., Masters, C. L., Bourgeat, P., Fripp, J., Villemagne, V. L., & Rowe, C. C. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104450 · Cited by 37
Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan
Shekari, M., Verwer, E. E., Yaqub, M. M., Daamen, M., Buckley, C. J., Frisoni, G. B., Visser, P. J., Farrar, G., Barkhof, F., Gispert, J. D., et al. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00588-x · Cited by 42
Wang, C., Tachimori, H., Yamaguchi, H., Sekiguchi, A., Li, Y., Yamashita, Y., & Initiative, F. A. D. N. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02819-w · Cited by 39
Hu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers
Bouteloup, V., Villain, N., Vidal, J., González‐Ortiz, F., Yuksekel, I., dos Santos, C. P., Schraen‐Maschke, S., Pellegrin, I., Lehmann, S., Blennow, K., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0142 · Cited by 48
The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial
Mummery, C. J., Mayorga, A. J., Simmons, A., Chow, T. W., Burgess, B., Nguyen, T., 高晶晶, Budda, B., Park, L. Q., Gupta, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04273-1 · Cited by 60
“Previous studies showed evidence of significant reductions in plasma tau biomarkers (p-tau217 and p-tau181), GFAP and Aβ 42/40 in response to treatment with ATTs 4,30,38 and significant reductions from baseline in plasma p-tau181 after treatment with a selective anti-oligomer therapy 39 .”
Self-citationGiorgio, J., Jagust, W. J., Baker, S. L., Landau, S. M., Tiňo, P., Kourtzi, Z., & Initiative, A. D. N. (2022) · Nature Communications · doi:10.1038/s41467-022-28795-7 · Cited by 48
“To model patient trajectories of future tau accumulation we used longitudinal FTP-PET.”
InfluentialJeong, S. Y., Suh, C. H., Shim, W. H., Lim, J., Lee, J., & Kim, S. J. (2022) · Neurology · doi:10.1212/wnl.0000000000201019 · Cited by 60
“001; Figures 2 and 3) compared with other agents.(15-34)”
BackgroundMethodResultInfluentialDhadda, S., Kanekiyo, M., Li, D. X., Swanson, C. J., Irizarry, M. C., Berry, S. M., Kramer, L. D., & Berry, D. A. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01129-x · Cited by 49
“The inclusion of an interaction term of baseline by visit is consistent with other analysis models [9, 10].”
ResultQiao, Y., Gu, J., Yu, M., Chi, Y., & Ma, Y. (2024) · CNS Drugs · doi:10.1007/s40263-024-01067-2 · Cited by 38
“Only a phase II trial of donazumab was involved in our NMA, and Mintun et al. considered no definitive conclusions could be drawn regarding the difference between groups in the change in ADAS-Cog score [31].”
Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease
Spotorno, N., Strandberg, O. T., Stomrud, E., Janelidze, S., Blennow, K., Nilsson, M., van Westen, D., & Hansson, O. (2023) · Brain · doi:10.1093/brain/awad428 · Cited by 48
“1,2,5 These counter-intuitive results might be due to micro-structural changes, reflecting, for example, changes in the neuroinflammatory response or fluid shift between the intra and extra cellular or intravascular space.”
Zhang, M., Wang, W., Ye, Q., Fu, Y., Li, X., Yang, K., Gao, F., Zhou, A., Wei, Y., Tian, S., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01384-0 · Cited by 44
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 42
Taylor, X., Noristani, H. N., Fitzgerald, G. J., Oluoch, H., Babb, N., McGathey, T., Carter, L., Hole, J. T., Lacor, P. N., Demattos, R. B., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00758-0 · Cited by 52
“Several large late-stage clinical trials have substantiated the success of this strategy, showcasing significant improvements in soluble biomarkers, reduction of amyloid pathology, and cognitive decline [2–4] validating the long-debated amyloid cascade hypothesis [5].”
BackgroundYarbro, J. M., Shrestha, H. K., Wang, Z., Zhang, X., Zaman, M., Chu, M., Wang, X., Yu, G., & Peng, J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00874-5 · Cited by 46
“Recently, the U.S. Food and Drug Administration (FDA) approved several Aβ-targeting treatments, including aducanumab [2], lecanemab [3], and donanemab [4].”
Sun, T., Shi, Q., Zhang, Y., Power, C., Hoesch, C., Antonelli, S., Schroeder, M. K., Caldarone, B. J., Taudte, N., Schenk, M., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.037 · Cited by 42
Brain volume loss due to donanemab
Ayton, S. (2021) · European Journal of Neurology · doi:10.1111/ene.15007 · Cited by 38
Targeted protein degraders march towards the clinic for neurodegenerative diseases
Kumar, D., & Hassan, M. I. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101616 · Cited by 38
Brain Shrinkage in Anti–β-Amyloid Alzheimer Trials: Neurodegeneration or Pseudoatrophy?
Barkhof, F., & Knopman, D. S. (2023) · Neurology · doi:10.1212/wnl.0000000000207268 · Cited by 38
Woo, M. S., Tissot, C., Lantero‐Rodriguez, J., Snellman, A., Therriault, J., Rahmouni, N., Macedo, A. C., Servaes, S., Wang, Y., Arias, J. F., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13528 · Cited by 37
“For example, during the main study period of the TRAILBLAZER-ALZ 2 29 trial that evalu-atedtheA β -targetingantibodydonanemab,pTau-217wassignificantly reducedby23%inthetreatmentarmwhereastheA β loadwasreduced by 85 centiloids.”
BackgroundPadilla-Godínez, F. J., Vázquez-García, E. R., Trujillo-Villagrán, M. I., Soto-Rojas, L. O., Palomero‐Rivero, M., Hernández-González, O., Pérez-Eugenio, F., Collazo-Navarrete, O., Arias-Carrión, Ó., & Guerra‐Crespo, M. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1570553 · Cited by 47
“These antibodies recognize partly different antigenic sites on oligomers of A β , except for donanemab that binds to an specific epitope in plaques (Mintun et al., 2021).”
Alzheimer disease seen through the lens of sex and gender
Castro‐Aldrete, L., Einsiedler, M., Martínková, J., Depypere, H. T., Ang, T. F. A., Mielke, M. M., Sindi, S., Eyre, H. A., Au, R., Dimech, A. S., et al. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01071-0 · Cited by 49
Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies
Fleming, S. M., Davis, A., & Simons, E. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108870 · Cited by 40
Rofo, F., Meier, S. R., Metzendorf, N. G., Morrison, J. I., Petrovic, A., Syvänen, S., Sehlin, D., & Hultqvist, G. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01283-y · Cited by 43
Salloway, S., Pain, A., Lee, E., Papka, M., Ferguson, M. B., Wang, H., Hu, H., Lu, M., Oru, E., Ardayfio, P. A., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70293 · Cited by 37
“13,14,19,20 The key secondary outcomes”
Self-citationMachine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
Karlsson, L., Vogel, J., Arvidsson, I., Åström, K., Strandberg, O., Seidlitz, J., Bethlehem, R. A. I., Stomrud, E., Ossenkoppele, R., Ashton, N. J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14600 · Cited by 43
“5–8 With emerging disease-modifyingtherapiesforAD, 9,10 includingtau-targetingtherapiesunder development, 11 it is crucial to find ways to reduce the need for PET scans due to their relative inaccessibility and costliness, while still preserving the ability to estimate the load and distribution of…”
Jiang, Y., Uhm, H., Ip, F. C., Ouyang, L., Lo, R. M. N., Cheng, E. Y. L., Cao, X., Tan, C. M. C., Law, B. C. H., Ortiz‐Romero, P., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13676 · Cited by 36
Perspective for Molecular Dynamics Simulation Studies of Amyloid-β Aggregates
Okumura, H. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c06051 · Cited by 38
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
“ARIAs were reported in clinical trials investigating the safety and efficacy of almost all mAbs, generally dose-dependent [115–117].”
BackgroundAlzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention
Teipel, S. J., Gustafson, D., Ossenkoppele, R., Hansson, O., Babiloni, C., Wagner, M., Riedel-Heller, S. G., Kilimann, I., & Tang, Y. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262239 · Cited by 48
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 41
Progression models for repeated measures: Estimating novel treatment effects in progressive diseases
Rakêt, L. L. (2022) · Statistics in Medicine · doi:10.1002/sim.9581 · Cited by 40
“In the proportional slowing model (7), such nonlinear interaction between treatment and subgroup membership can be modeled efficiently by including one additional parameter ρ that describes the relation between the speed of”
BackgroundMethodResultInfluentialGustavsson, T., Metzendorf, N. G., Wik, E., Roshanbin, S., Julku, U. H., Chourlia, A., Nilsson, P., Andersson, K. G., Laudon, H., Hultqvist, G., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01236-3 · Cited by 38
Gibson, L. L., Ruiz, C. A., Chong, J. R., Ballard, C. G., & Aarsland, D. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001173 · Cited by 38
Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA
Sin, M., ZAMRINI, E. Y., Ahmed, A., Nho, K. T., & Hajjar, I. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216792 · Cited by 44
“For example, several clinical trials have reported an ARIA-E incidence of up to 55% in ApoE e4 (homozygous) carriers receiving the N-terminus amyloid β targeted medications [32,49,50] compared to treatments targeting the mid-domain or C-terminus of amyloid β [51,52].”
BackgroundLee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 49
“In a randomized phase 2 trial conducted on patients with early symptomatic Alzheimer’s disease, the administration of donanemab demonstrated a modest reduction in cognitive and functional decline when compared to a placebo [47].”
BackgroundResultInfluentialCousins, K. A. Q., Korecka, M., Wan, Y., Vulaj, A., Brown, C. D., Tropea, T. F., Lee, E. B., Tosun, D., Landau, S. M., Okonkwo, O. C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70469 · Cited by 44
“For ADNI, amyloid status was determined by Centiloids ≥ 25, 34,35 and severity was computed using Centiloids.”
Simrén, J., Brum, W. S., Ashton, N. J., Benedet, A. L., Karikari, T. K., Kvartsberg, H., Sjons, E., Lussier, F. Z., Chamoun, M., Stevenson, J., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01142-0 · Cited by 35
“In that trial, only patients with tau pathology which could be considered as moderate as indexed by tau PET SUVR in an AD-related topographic distribution were included [38].”
BackgroundLecanemab slows Alzheimer's disease: hope and challenges
Mead, S., & Fox, N. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00529-4 · Cited by 36
Wessels, A. M., Dennehy, E. B., Dowsett, S. A., Dickson, S. P., & Hendrix, S. B. (2023) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200127 · Cited by 35
“The iADRS was the primary outcome measure in the TRAILBLAZER-ALZ trial, a phase 2 study designed to evaluate the safety and efficacy of donanemab, developed by Eli Lilly and Company, in participants with early symptomatic AD (defined as mild cognitive impairment [MCI] or mild dementia due to AD).(8)”
MethodInfluentialSelf-citationAducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
Salloway, S., & Cummings, J. (2021) · Neurology · doi:10.1212/wnl.0000000000012451 · Cited by 34
Self-citationPlasma ATN(I) classification and precision pharmacology in Alzheimer's disease
Imbimbo, B. P., Watling, M., Imbimbo, C., & Nisticò, R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13084 · Cited by 34
Lessons from antiamyloid-β immunotherapies in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 40
Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects
Li, J., Liao, W., Huang, D., Ou, M., Chen, T., Wang, X., Zhao, R., Zhang, L., Mei, L., Liu, J., et al. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215375 · Cited by 38
Nimmo, J., Smith, H., Wang, C. Y., Teeling, J. L., Nicoll, J. A. R., Verma, A. K., Dodart, J., Liu, Z., Feng, L., & Carare, R. O. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02381-5 · Cited by 39
“Immunotherapy trials in Alzheimer’s disease have shown more progress towards clinical benefit at the earliest disease stages [30], highlighting the necessity for early intervention with immunotherapy.”
BackgroundTrends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
Martins, A. C., Oshiro, M. Y., Alberício, F., de la Torre, B. G., Pereira, G. J. V., & Gonzaga, R. V. (2022) · Biomedicines · doi:10.3390/biomedicines10092325 · Cited by 43
“However, these two drugs still need further supporting clinical evidence to compete with Aducanumab and enter the market [23,96,97].”
BackgroundIndividuals with Alzheimer's disease and low tau burden: Characteristics and implications
Landau, S. M., Lee, J., Murphy, A., Ward, T. J., Harrison, T. M., Baker, S. L., DeCarli, C. S., Harvey, D. J., Tosun, D., Weiner, M. W., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13609 · Cited by 37
“Theregionalpatternofhigh-rankedslopes differed from the regional pattern of high-ranked baseline tau in that medial temporal slopes were highly ranked in the unimpaired A + T − group only (see Supplementary Materials for complete region rank lists).”
Tau; One Protein, So Many Diseases
Tabeshmehr, P., & Eftekharpour, E. (2023) · Biology · doi:10.3390/biology12020244 · Cited by 33
“Human AD patients Donanemab Slowing tau accumulation Tau accumulation [107,108]”
BackgroundLu, M., Kim, M. J., Collins, E. C., Shcherbinin, S., Ellinwood, A. K., Yokoi, Y., Brooks, D. A., Hansson, O., Knopman, D. S., Sims, J. R., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.3869 · Cited by 38
Self-citationBaviskar, P. S., & Mahajan, H. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102990 · Cited by 47
Bullich, S., Mueller, A., Santi, S. D., Koglin, N., Krause, S., Kaplow, J. M., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01048-x · Cited by 34
“Indeed, several studies have used tau as a biomarker for reduction of amyloid-beta [19] and the TRAILBLAZER-ALZ study (NCT04437511), for the first time, used tau PET imaging as an inclusion criterion of a clinical trial of an anti-amyloid monoclonal antibody [20].”
MethodLi, X., Tang, X., Zeng, J., Duan, L., Hou, Z., Li, L., Guo, Y., Chai, C., Liu, J., Wang, Y., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.020 · Cited by 32
Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK
Laurell, A. A. S., Venkataraman, A. V., Schmidt, T., Montagnese, M., Mueller, C., Stewart, R. J., Lewis, J. R., Mundell, C., Isaacs, J. D., Krishnan, M. S., et al. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2023.166 · Cited by 35
“This was followed by the publication of a similar phase 2 trial of donanemab (TRAILBLAZER-ALZ (4)) and subsequently the phase 3 trials of lecanemab (CLARITY-AD (1)) and donanemab (TRAILBLAZER-ALZ 2 (2)) which more definitively reported slowing of decline in cognitive, functional, and other outcomes.”
MethodZülke, A. E., Pabst, A., Luppa, M., Oey, A., Weise, S., Fankhänel, T., Kosilek, R. P., Schillok, H., Brettschneider, C., Czock, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14097 · Cited by 33
Bi, D., Bao, H., Yang, X., Wu, Z., Yang, X., Xu, G., Liu, X., Wan, Z., Liu, J., He, J., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.01.030 · Cited by 35
Joie, R. L., Cummings, J. L., Dage, J. L., Galasko, D. R., Ikonomović, M. D., Karikari, T. K., Landau, S. M., Llibre‐Guerra, J. J., Mummery, C. J., Ossenkoppele, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70997 · Cited by 38
“3,4,6,8 -”
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
“…recent progress has been made toward developing novel antibody-based pharmacotherapies such as aducanumab (Sevigny et al. 2016) and donanemab (Mintun et al. 2021), controversy remains whether these will prove safe, accessible, and substantially effective treatments for patients with AD…”
Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases
Rickenbach, C., & Gericke, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.806260 · Cited by 37
Chen, L., Cruz, E., Oikari, L. E., Padmanabhan, P., Song, J. H., & Götz, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114517 · Cited by 38
Greenberg, B., Pettigrew, C. A., Soldan, A., Wang, J., Wang, M., Darrow, J. A., Albert, M., & Moghekar, A. (2022) · Neurology · doi:10.1212/wnl.0000000000200953 · Cited by 34
“A recent example of baseline measures guiding trial design was implemented in the phase 2 study of the antiamyloid immunotherapy donanemab, in which enrollment was based on specific levels of both amyloid and tau, as measured by PET scans.(50)”
MethodNew Perspectives of Taxifolin in Neurodegenerative Diseases
Yang, R., Yang, X.-X., & Zhang, F. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230203101107 · Cited by 32
“This process was accompanied by a release of various inflammatory mediators, and these mediators were closely associated with the progression and severity of AD [113-115].”
BackgroundLantero‐Rodriguez, J., Tissot, C., Snellman, A., Servaes, S., Benedet, A. L., Rahmouni, N., Montoliu‐Gaya, L., Therriault, J., Brum, W. S., Stevenson, J., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13119 · Cited by 32
“48 Thus,NTA-taumeasurementscouldpotentially be useful in clinical settings, providing a cost-effective tool capable of tracking tau pathology in vivo, and in clinical trials, as an inclusion/exclusion criterion, 49 or to potentially monitor the downstream effects of anti-A β drugs.”
BackgroundNeuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein
Stoner, A. J., Fu, L., Nicholson, L., Zheng, C., Toyonaga, T., Spurrier, J. M., Laird, W., Cai, Z., & Strittmatter, S. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01345-z · Cited by 37
“Recent clinical trials document some slowing of disease progression during treatment with certain anti-Aβ antibodies [3, 4].”
BackgroundThe Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 33
“The notable exceptions to this are solanezumab and The time course of treatment also seems to be associated with ARIA risk, with multiple studies showing higher ARIA risk earlier in the treatment course and lower risk later in the treatment course [26,34–37].”
ResultA critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 32
Recent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 42
“Donanemab, an immunoglobulin G1 antibody, targets a specific epitope unique to mature brain amyloid plaques [73].”
Advanced nano delivery system for stem cell therapy for Alzheimer's disease
Pan, Y., Li, L., Cao, N., Liao, J., Chen, H., & Zhang, M. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122852 · Cited by 40
The 2021 yearbook of Neurorestoratology
Sharma, H. S., Chopp, M., Chen, L., Sarnowska, A., Xue, M., Ao, Q., Siniscalco, D., Chen, L., Hawamdeh, Z. M., & Huang, H. (2022) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2022.100008 · Cited by 34
Song, C., Zhang, T., & Zhang, Y. (2022) · Molecules · doi:10.3390/molecules27196751 · Cited by 34
“Donanemab appears to have demonstrated significant plaque clearance efficacy and was recently assessed in a phase 2 trial for its efficacy and safety for the treatment of early AD [58,60].”
BackgroundLecanemab reduces brain amyloid-β and delays cognitive worsening
Knopman, D. S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100982 · Cited by 35
Mattke, S., Gustavsson, A., Jacobs, L., Kern, S., Palmqvist, S., Eriksdotter, M., Skoog, I. G., Winblad, B. G., Wimo, A. B., & Jönsson, L. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.94 · Cited by 33
Tobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 38
“…and it works by targeting N-terminally truncated pyroglutamate-modified A β (A β pE ), a type of A β only found in plaques in the brain and not in cerebrospinal fluid (CSF) nor plasma (Harigaya et al., 2000; DeMattos et al., 2012; Alawode et al., 2021; Mintun et al., 2021; Reardon, 2023a).”
BackgroundLiu, Z., Shi, D., Cai, Y. Q., Li, A., Lan, G., Sun, P., Liu, L., Zhu, Y., Yang, J., Zhou, Y., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01458-z · Cited by 39
“Recently, three anti-Aβ drugs, including Aducanumab [28], Lecanemab [29], and Donanemab [30] showed positive results in phase 3 clinical trials.”
BackgroundDisease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
Zhang, Y., Chen, J., Li, Y., Jiao, B., & Luo, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102595 · Cited by 38
Arroyo-Pacheco, N., Sarmiento-Blanco, S., Vergara-Cadavid, G., Castro-Leones, M., & Contreras‐Puentes, N. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102620 · Cited by 44
Citrullination of Amyloid-β Peptides in Alzheimer’s Disease
Mukherjee, S., Perez, K. A., Dubois, C., Nisbet, R. M., Li, Q., Varghese, S., Jin, L., Birchall, I. E., Streltsov, V. A., Vella, L. J., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00474 · Cited by 32
Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside
Musiek, E. S., Gómez‐Isla, T., & Holtzman, D. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci154889 · Cited by 32
“Since then, both lecanemab and donanemab have also demonstrated potent plaque-clearing effects and have shown evidence of modest slowing of cognitive decline in phase II studies of very mild AD (7, 8).”
BackgroundSeeding, maturation and propagation of amyloid β-peptide aggregates in Alzheimer’s disease
Li, X., Ospitalieri, S., Robberechts, T., Hofmann, L., Schmid, C., Upadhaya, A. R., Koper, M. J., Arnim, C. A. F. V., Kumar, S., Willem, M., et al. (2022) · Brain · doi:10.1093/brain/awac202 · Cited by 45
Scala, C. D., Armstrong, N., Chahinian, H., Chabrière, É., Fantini, J., & Yahi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113383 · Cited by 34
Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model
Oliveira, D. V., Coupland, K., Shao, W., Jin, S., Gaudio, F. D., Wang, S., Fox, R., Rutten, J. W., Sandin, J., Zetterberg, H., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216556 · Cited by 36
Mohs, R. C., Bakker, A., Rosenzweig-Lipson, S. J., Rosenblum, M., Barton, R. L., Albert, M., Cohen, S., Zeger, S. L., & Gallagher, M. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12446 · Cited by 39
Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease
Thomas, G. E. C., Hannaway, N., Zarkali, A., Shmueli, K., & Weil, R. S. (2024) · Movement Disorders · doi:10.1002/mds.29702 · Cited by 36
Khan, M. S., Qureshi, N., Khan, R., Son, Y., & Maqbool, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1578138 · Cited by 38
“It is in ongoing phase-3 clinical trial stage (Mintun et al., 2021; Kim et al., 2025).”
Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease
Sehlin, D., Hultqvist, G., Michno, W., Aguilar, X., Dahlén, A. D., Cerilli, E., Bucher, N. M., van den Broek, S. L., & Syvänen, S. (2025) · The journal of prevention of Alzheimer's disease · doi:10.1016/j.tjpad.2025.100214 · Cited by 30
Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer’s disease
Imabayashi, E., Tamamura, N., Yamaguchi, Y., Kamitaka, Y., Sakata, M., & Ishii, K. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01769-x · Cited by 33
Giangrande, C., Delatour, V., Andréasson, U., Blennow, K., Gobom, J., & Zetterberg, H. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12465 · Cited by 48
“quadrupole equipment) were also compared to the results obtained by enzyme-linked immunosorbent assay (ELISA) (INNOTEST β-amyloid [1-42] from Fujirebio) and presented a quite high correlation with the ELISA results (r2 > 0.”
Oliver, C., Li, H., Biswas, B., Woodstoke, D., Blackman, J., Butters, A. F., Drew, C. J. G., Gabb, V. G., Harding, S. A., Hoyos, C. M., et al. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101869 · Cited by 37
Synthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, J., Burkett, B. J., Min, H.-K. P., Senjem, M. L., Dicks, E., Corriveau‐Lecavalier, N., Mester, C. T., Wiste, H. J., Lundt, E. S., Murray, M. E., et al. (2023) · Brain · doi:10.1093/brain/awad346 · Cited by 43
“20 However, at present, tau-PET is not widely accessible to patients compared to other neuroimaging methods.”
ResultDantas, J. M., Mutarelli², A. M., Navalha, D. D. P., Dagostin, C. S., Romeiro, P. H. C. L., Felix, N. S., Nogueira, A., Batista, S., Teixeira, L., & Caramelli, P. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07194-w · Cited by 32
Burnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 36
“222 Further, it was used to stratify patients in the donanemab Phase 3 trial, which also returned positive results.”
MethodDubbelman, M. A., Hendriksen, H. M. A., Harrison, J., Vijverberg, E. G. B., Prins, N. D., Kroeze, L. A., Ottenhoff, L., van Leeuwenstijn, M. S. S. A., Verberk, I. M. W., Teunissen, C. E., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207978 · Cited by 27
Greenberg, E. F., Voorbach, M. J., Smith, A. G., Reuter, D. R., Zhuang, Y., Wang, J.-Q., Wooten, D., Asque, E., Hu, M., Hoft, C., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36483 · Cited by 34
“In contrast, in clinical studies, anti-amyloid therapeutics can achieve near-complete removal of amyloid plaques with only a 20 – 30 % reduction in cognitive decline at weeks 76 – 78 [2,6].”
BackgroundIncreases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2024) · Brain · doi:10.1093/brain/awae216 · Cited by 39
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, H., Cummings, J. L., Boxer, A. L., Staffaroni, A. M., Knopman, D. S., Rizzo, S. J. S., Territo, P. R., Arnold, S. E., Ballard, C. G., Beher, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14250 · Cited by 28
Default mode network tau predicts future clinical decline in atypical early Alzheimer’s disease
Katsumi, Y., Howe, I., Eckbo, R., Wong, B., Quimby, M., Hochberg, D., McGinnis, S. M., Putcha, D., Wolk, D. A., Touroutoglou, A., et al. (2024) · Brain · doi:10.1093/brain/awae327 · Cited by 32
Identification of late-stage tau accumulation using plasma phospho-tau217
Woo, M. S., Therriault, J., Jonaitis, E. M., Wilson, R. E., Langhough, R. E., Rahmouni, N., Benedet, A. L., Ashton, N. J., Tissot, C., Lantero‐Rodriguez, J., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105413 · Cited by 35
Zhuang, X., Jie, L., Song, Y., Ban, R., Zhao, X., Xia, Z., Wang, Z., & Zhang, G. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08815-z · Cited by 35
“Ongoing research (Arndt et al., 2018; Mintun et al., 2021; Swanson et al., 2021) is exploring immunotherapies, such as monoclonal antibodies (mAbs) and vaccines, to modulate immune responses or clear pathological protein accumulations.”
Bonnar, O., Eyre, B., & van Veluw, S. J. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00535 · Cited by 32
“Promising data that have emerged from anti-A β immunotherapy trials, suggest a positive downstream in fl uence of A β removal on levels of phosphorylated tau [113 – 115].”
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.